LEGISLATIVE FISCAL OFFICE
Fiscal Note
Fiscal Note On: SB 148 SLS 24RS 311
Bill Text Version: ENROLLED
Opp. Chamb. Action:
Proposed Amd.:
Sub. Bill For.:
Date: May 21, 2024 12:09 PM Author: MIZELL
Dept./Agy.: Insurance and Office of Group Benefits
Subject: Postpartum Depression Override from Step Therapy/Fail First Analyst: Patrice Thomas
HEALTH/ACC INSURANCE EN NO IMPACT See Note Page 1 of 1
Provides relative to postpartum depression. (8/1/24)
Under current law, when medications for the treatment of any medical condition are restricted for use by any health
coverage plan through a step therapy or fail first protocol, the prescribing practitioner shall have access to a clear and
convenient process to expeditiously request an override of the restriction. Proposed law creates an additional override for the
treatment of postpartum depression by a prescription drug for postpartum depression under the step therapy or fail first
protocol that is not indicated by the United States Food and Drug Administration (FDA) for postpartum depression on the
prescription drug’s approved labeling.
EXPENDITURES 2024-25 2025-26 2026-27 2027-28 2028-29 5 -YEAR TOTAL
State Gen. Fd. $0 $0 $0 $0 $0 $0
Agy. Self-Gen. $0 $0 $0 $0 $0 $0
Ded./Other $0 $0 $0 $0 $0 $0
Federal Funds $0 $0 $0 $0 $0 $0
Local Funds $0 $0 $0 $0 $0 $0
Annual Total $0 $0 $0 $0 $0 $0
REVENUES 2024-25 2025-26 2026-27 2027-28 2028-29 5 -YEAR TOTAL
State Gen. Fd. $0 $0 $0 $0 $0 $0
Agy. Self-Gen. $0 $0 $0 $0 $0 $0
Ded./Other $0 $0 $0 $0 $0 $0
Federal Funds $0 $0 $0 $0 $0 $0
Local Funds $0 $0 $0 $0 $0 $0
Annual Total $0 $0 $0 $0 $0 $0
EXPENDITURE EXPLANATION
There is no anticipated direct material effect on governmental expenditures as a result of this measure. Proposed law will
have no direct material effect on pharmacy and medical claims expenditures in the Office of Group Benefits (OGB) or health
insurance policies issued under the health insurance exchanges/marketplace. Proposed law creates another override from
the requirement of step therapy or fail first protocols for postpartum depression for which the prescription drug for
postpartum depression that has not been indicated by the FDA for postpartum depression on the prescription drug’s
approved labeling.
REVENUE EXPLANATION
There is no anticipated direct material effect on governmental revenues as a result of this measure.
Senate Dual Referral Rules House
13.5.1 >= $100,000 Annual Fiscal Cost {S & H} 6.8(F)(1) >= $100,000 SGF Fiscal Cost {H & S}
Alan M. Boxberger
13.5.2 >= $500,000 Annual Tax or Fee 6.8(G) >= $500,000 Tax or Fee Increase
Change {S & H} or a Net Fee Decrease {S} Legislative Fiscal Officer


Statutes affected:
SB148 Original: 22:1053(K)